Lysozyme enhances renal excretion of advanced glycation endproducts in vivo and suppresses adverse AGE-mediated cellular effects in vitro: A potential AGE sequestration therapy for diabetic nephropathy?

Molecular Medicine

Volumn 7, Issue 11, 2001, Pages 737-747

  Zheng, Feng ^a   Cai, Weijing ^a   Mitsuhashi, Tomoko ^a   Vlassara, Helen ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BOVINE SERUM ALBUMIN; COLLAGEN TYPE 4; GELATINASE A; GELATINASE B; IODINE 125; LYSOZYME; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR B; SOMATOMEDIN C; TENASCIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CHEMICAL INTERACTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEGRADATION; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; GENE ACTIVATION; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY CLEARANCE; MACROPHAGE; MALE; MESANGIUM CELL; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEINURIA; RAT; URINARY EXCRETION;

EID: 0035716821     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03401963     Document Type: Article

References (47)

1. Ageing growth factors; a role in diabetic vascular disease?
2. Advanced glycosylation endproducts
3. Activation of receptor for advanced glycation endproducts: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis
4. Role of oxidative stress in development of complications in diabetes
5. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure
6. Mechanisms for the formation of glycoxidation products in end-stage renal disease
7. Toxicity of low levels of methylglyoxal: Depletion of blood glutathione and adverse effects on glucose tolerance in mice
8. Imidazolium crosslinks derived from reaction of lysine with glyoxal and methylglyoxal are increased in serum proteins of uremic patients: Evidence for increased oxidative stress in uremia
9. Pathogenic effects of advance glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging
10. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure
11. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking
12. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo
13. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation
14. Low AGE-diet ameliorates nephropathy in non-obese diabetic (NOD) mice
15. Retriction of AGE content of food, without lowering protein intake prevents diabetic nephropathy (DN) in mice
16. Pharmacological aspects and therapeutic applications of lysozymes
17. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif
18. Depletion of reactive advanced glycation endproducts from diabetic uremic sera by a lysozyme-linked matrix
19. Immunochemical detection of advanced glycosylation end products in vivo
20. Standardizing the immunological easurement of advanced glycation endproducts using normal human serum
21. Binding and modification of proteins by methylglyoxal under physiological conditions a kinetic and mechanistic study with N-alpha-acetylarginine, N-alpha-acetylcysteine, and N-alpha-acetyllysine, and bovine serum albumin
22. εN-(Carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins
23. Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine
24. Differential expression and function of advanced glycation endproduct (AGE)-receptor genes in NOD mouse kidneys; possible role in diabetic and non-diabetic renal disease
25. Receptors for advanced glycosylation endproducts in human brain: Role in brain homeostasis
26. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor
27. Human and rat mesangial cell receptors for glucose-modified proteins: Potential role in kidney tissue remodelling and diabetic nephropathy
28. Mesangial cells from diabetic NOD mice constitutively secrete increased amounts of insulin-like growth factor-I
29. Studies by competitive PCR of glomerulosclerosis in growth hormone transgenic mice
30. Matrix metalloproteinases in renal development
31. Mesangial cells from transgenic mice with progressive glomerulosclerosis exhibit stable, phenotypic changes including undetectable MMP-9 and increased type IV collagen
32. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal-TGFβ antibody in db/db diabetic mice
33. Renal fate of circulating advanced glycation end products (AGE): Evidence for reabsorption and catabolism of AGE peptides by renal proximal tubular cells
34. Reaction of advanced glycation endproducts with renal tissue from normal and streptozotocin-induced diabetic rats: An ultrastructural study using colloidal gold cytochemistry
35. Quantification of renal low-molecular-weights protein handling in the intact rat
36. Drug-targeting to the kidney: Renal delivery and degradation of a naproxen-lysozyme conjugate in vivo
37. εN-(Carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression
38. Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors
39. Vascular complications of diabetes and the role of advanced glycosylation end products
40. Cachectin/tnf and IL-1 induced by glucose-modified proteins: Role in normal tissue remodeling
41. Advanced glycation and the development of diabetic complications. Unifying the involvement of glucose, methylglyoxal and oxidative stress
42. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis
43. Administration of AGEs in vivo induces genes implicated in diabetic glomerulosclerosis
44. Binding of lysozyme to lipopolysaccharide suppresses-tumor necrosis factor production in vivo
45. Lysozyme and RNAses as anti-HIV components in β-core preparations of human chorionic gonadotropin
46. Overexpression of human recombinant lysozyme (huLZ) by macrophages leads to enhanced glycotoxin uptake and clearance without cell activation: A new model approach for the prevention of diabetic complications
47. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts